All IndicationsOncologyApprovedApprovedPhase 3Phase 3Phase 3Phase 2Phase 2
🎗️
Pancreatic Cancer
9
Companies
9
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
RVMD
Revolution Medicines
Rasonque
TRAX
Trax Pharmaceuticals
daraxonrasib
RVMDW
Revolution Medicines, Inc.
daraxonrasib
ALPMY
Astellas Pharma
Setidegrasib
APTOF
Aptose Biosciences Inc.
Virulizin®
XBIT
XBiotech Inc.
XB2001 or Placebo
GRTX
Galera Therapeutics, Inc.
GC4419
PPCB
Propanc Biopharma
PRP
FVNNU
Forty Seven Inc
RASolute 302
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| RVMD Revolution Medicines | Rasonque | Approved | — | — | — |
| TRAX Trax Pharmaceuticals | daraxonrasib | Approved | — | — | — |
| RVMDW Revolution Medicines, Inc. | daraxonrasib | Phase 3 | — | — | — |
| ALPMY Astellas Pharma | Setidegrasib | Phase 3 | — | — | — |
| APTOF Aptose Biosciences Inc. | Virulizin® | Phase 3 | — | — | — |
| XBIT XBiotech Inc. | XB2001 or Placebo | Phase 2 | — | — | — |
| GRTX Galera Therapeutics, Inc. | GC4419 | Phase 2 | — | — | — |
| PPCB Propanc Biopharma | PRP | — | — | — | — |
| FVNNU Forty Seven Inc | RASolute 302 | — | — | — | — |
Development Stage Distribution
Unknown
2
Approved
2
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.